Cantor Fitzgerald Weighs in on Innoviva FY2025 Earnings

Innoviva, Inc. (NASDAQ:INVA) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Innoviva in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the biotechnology company will post earnings per share of $1.55 for the year. The consensus estimate for Innoviva’s current full-year earnings is $0.33 per share.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.25). The business had revenue of $89.51 million for the quarter. Innoviva had a return on equity of 20.84% and a net margin of 18.31%.

Separately, StockNews.com cut Innoviva from a “buy” rating to a “hold” rating in a report on Tuesday, December 31st.

Innoviva Stock Performance

Shares of INVA opened at $18.75 on Wednesday. The firm’s fifty day simple moving average is $18.37 and its two-hundred day simple moving average is $18.77. Innoviva has a 12 month low of $14.32 and a 12 month high of $21.28. The stock has a market capitalization of $1.17 billion, a P/E ratio of 27.17 and a beta of 0.54. The company has a current ratio of 1.79, a quick ratio of 1.64 and a debt-to-equity ratio of 0.38.

Hedge Funds Weigh In On Innoviva

Several institutional investors have recently made changes to their positions in the stock. Exchange Traded Concepts LLC increased its position in Innoviva by 4.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 162,005 shares of the biotechnology company’s stock valued at $2,811,000 after buying an additional 7,220 shares in the last quarter. Ritholtz Wealth Management raised its position in shares of Innoviva by 3.9% during the fourth quarter. Ritholtz Wealth Management now owns 74,439 shares of the biotechnology company’s stock worth $1,292,000 after purchasing an additional 2,782 shares during the period. CWA Asset Management Group LLC lifted its holdings in shares of Innoviva by 29.1% in the 4th quarter. CWA Asset Management Group LLC now owns 38,355 shares of the biotechnology company’s stock worth $665,000 after purchasing an additional 8,645 shares in the last quarter. JPMorgan Chase & Co. grew its position in Innoviva by 14.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 578,243 shares of the biotechnology company’s stock valued at $11,166,000 after purchasing an additional 72,039 shares during the period. Finally, World Investment Advisors LLC bought a new stake in Innoviva during the 3rd quarter valued at $217,000. Institutional investors and hedge funds own 99.12% of the company’s stock.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.